Plain-English translation of NCT06698614 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at the University of Edinburgh are testing whether manganese-enhanced magnetic resonance imaging (MEMRI) — a new type of MRI scan — can help predict which patients with kidney disease will develop heart problems. The scan uses a safe contrast agent that behaves like calcium, allowing doctors to see how well the heart and kidneys are handling minerals. This imaging approach could help identify patients at highest risk for serious complications.
Currently, doctors have no reliable way to predict which kidney disease patients will go on to develop heart disease or permanent kidney damage. By identifying these high-risk patients early, treatment could be started sooner to prevent serious complications.
You likely qualify if…
You likely don't qualify if…
Depending on which kidney disease group you join, you will have one or more MRI scans over several months. The scan is painless and similar to a standard MRI, but uses a special contrast agent injected into your vein. Some participants will have follow-up scans at 3–6 months to see whether their condition improved or worsened. The entire study involves clinic visits, blood tests, and imaging — all designed to help doctors understand how kidney disease affects the heart.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United Kingdom